Produção Nacional
Revisado por pares
Safety and Immunovirologic Outcomes with Maraviroc Combination Regimens in Patients with a History of Past Treatment Failures and Virologic Resistance in Brazil: An Open-Label, Multicenter Phase 3b Study
2013; Mary Ann Liebert, Inc.; Volume: 29; Issue: 9 Linguagem: Inglês
10.1089/aid.2012.0330
ISSN1931-8405
AutoresJuvencio Furtado, José Valdez Madruga, Eliana L. Bicudo, Margareth da Eira, Max Igor Banks Ferreira Lopes, Eduardo Martins Netto, Marília Santini-Oliveira, Olavo Henrique Munhoz Leite, Alcyone Artioli Machado, Unaí Tupinambás, José L. de Andrade Neto, Maria Patelli Juliani Souza Lima, Rogério de Jesus Pedro, Antônio F.B. Miranda, David Salomão Lewi, Breno Santos, Simon Portsmouth, Dalia Wajsbrot, Lourenia M. Cassoli,
Tópico(s)HIV/AIDS Research and Interventions
ResumoMaraviroc is a first-in-class chemokine coreceptor type-5 (CCR5) antagonist with demonstrated immunovirologic activity in treatment-experienced (TE) patients with CCR5 (R5)-tropic HIV-1; however, experience in regimens containing newer antiretroviral agents is limited. The primary objective of this 96-week open-label, noncomparative, multicenter Phase 3b study (NCT00478231) was to assess the safety of maraviroc in combination with optimized background therapy (OBT), which could include recently introduced agents such as darunavir and raltegravir in TE patients in Brazil with R5 HIV-1 and limited therapeutic options. Immunovirologic activity was a secondary endpoint. Of 638 patients screened, 206 were treated and 125 completed the study. Approximately 70% were male; the mean age was 43.2 years. Most patients (65.0%) received an OBT combination of protease inhibitor plus nucleoside reverse transcriptase inhibitor. Adverse event (AE) and treatment-related AE incidence was 91.3% and 36.9%, respectively. The most common AEs were diarrhea, nasopharyngitis, and headache. Serious AEs and treatment-related serious AEs occurred in 16.5% and 4.4% of patients. Only eight patients (3.9%) discontinued due to AEs. Few AIDS-defining events were observed (4.9%). The proportion of patients with viral load 40% until week 48. At the end of treatment, 26.7% of patients had a viral load <400 copies/ml. Median CD4+ cell count increased throughout the study; the mean change from baseline to end of treatment was 174.1 cells/μl. In conclusion, maraviroc, combined with different agents from multiple classes, was well tolerated in highly TE patients. Maraviroc plus OBT was associated with an immunovirologic response in this population.
Referência(s)